Introduction
============

Benign prostatic hyperplasia (BPH) is the most common urological condition among elderly men, affecting approximately half of men over 80 years of age. It usually begins as a simple micronodular hyperplasia with a subsequent macroscopic nodular enlargement that may result in bladder outlet obstruction and the development of lower urinary tract symptoms (LUTS) ([@B3]).

As the prostate enlarges, it constricts the urethra, inducing various symptoms such as: weak urinary stream, incomplete bladder emptying, nocturia, dysuria, and bladder outlet obstruction ([@B44]). These symptoms which have been associated with BPH are known as LUTS ([@B8]).

Although the molecular and stromal mechanisms associated with the pathogenesis of this metabolic disorder have not yet been fully elucidated ([@B3]), several factors such as: inflammatory mediators, hormonal, dietary factors, environmental and oxidative stress have been implicated in its etiology ([@B69]).

Currently, the two major medications that are being used for the treatment of BPH include the α1-adrenergic receptor antagonists (doxazosin, terazosin, and tamsulosin) which alleviate LUTS by relaxation of smooth muscle in the prostate and the neck of the bladder; and the 5α-reductase inhibitors \[which inhibit the development of BPH through a reduction in dihydrotestosterone (DHT) production\].

While these conventional drugs have been found to be efficacious in the treatment of BPH, the adverse effects associated with them, ranging from impotence and gynaecomastia to orthostatic hypotension, abnormal ejaculation amongst others, have led to increased search for alternative means of managing this disease.

Although surgery has also been suggested to be an option, the cost and risks associated with it excludes it as a routine treatment. The trend then is increased search for alternative methods of managing this disease using natural remedies ([@B47]; [@B48]).

Polyphenols are the most abundant dietary antioxidants and are common constituents of many plant food sources, including fruits, vegetables, seeds, nuts, chocolate, wine, coffee, and tea. Natural polyphenols have increasingly gained public interest in recent times. This could be attributed to the emerging evidence that suggests their roles in the prevention of various disease that implicate free radicals/reactive oxygen species (ROS; [@B86]; [@B24],[@B25], [@B21]). However, the role of these polyphenols in the management of BPH and their mechanisms of action are yet to be reported. Hence, this article which reviewed the concept of management of BPH using dietary polyphenols.

Materials and Methods {#s1}
=====================

Literature search was carried out in several electronic data bases such as PubMed, Google Scholar, Medline, Agora, and Hinari from1970 to 2017 to identify the current status of knowledge on the contribution of dietary polyphenols to the management of BPH and their mechanisms of action. The findings from these data bases are therefore reported in this review.

Definition of Polyphenols
-------------------------

Polyphenol is a generic term for thousands of plant-based molecules that possess antioxidant properties. These polyphenols have been identified as secondary metabolites of plants that contain one or more hydroxyl groups attached to the ortho, meta or para positions on a benzene ring ([@B80]).

Over 8,000 identified polyphenols are present in foods and they have been found to play important roles in the maintenance of human health and wellness ([@B99]; [@B25]; [@B22]).

Classification of Polyphenols and Their Dietary Sources
-------------------------------------------------------

Polyphenols could be classified into five groups namely: (a) phenolic acids, (b) stilbenes, (c) lignans (d) flavonoids, and (e) curcuminoids ([@B23]; [@B63]; [@B21]).

1.  Phenolic acids are further divided into two subgroups which are: (i) hydroxybenzoic acids (example is gallic acid), found in tea and (ii) hydroxycinnamic acids. Examples of hydroxycinnamic acids are caffeic acid found in virtually all fruits ([@B64]); chlorogenic acid found in strawberries, pineapple, etc; and *p*-coumaric acid that is found in cereal grains ([@B63]).

2.  Stilbenes are found in red wines, red grape juice and peanuts ([@B102]; [@B78]) while resveratrol is the most common.

3.  Lignans: These groups of polyphenols include: secoisolariciresinol found in flaxseed ([@B63]) and sesamin found in sesame seed ([@B95]).

4.  Flavonoids could be found in fruits, vegetables, legumes, red wine, and green tea. They are further divided into eight subgroups namely: flavanols, flavonols, flavones, isoflavones, flavanones, anthocyanins, proanthocyanidins, and chalcones.

    1.  Flavanols (example is epigallocatechin gallate) are found in green and black tea ([@B50]).

    2.  Flavonols (examples are kaempferol and quercetin) could be found in onions, broccoli, and blueberries ([@B40]).

    3.  Anthocyanins (example is cyanin glucoside) could be found in highly pigmented fruits ([@B63]).

    4.  Flavones (examples include: apigenin, chrysin, and luteolin) could be found in Parsley and Celery ([@B63]).

    5.  Isoflavones (examples are daidzein and genistein) are found in soya and its processed products ([@B11]).

    6.  Flavanones (example is naringenin) could be found in grapefruit ([@B63]).

    7.  Chalcones are mainly abundant in beer. They are also abundant in fruits like citruses and apples; in certain vegetables such as shallot, tomatoes, potatoes, and bean sprouts and in various plants and spices (licorice, cardamom). Xanthohumol is the main prenylated chalcone, predominately found in beer ([@B72]; [@B21]).

5.  Curcuminoids represent another class of polyphenols; a typical example being curcumin which is found in *Curcuma longa* ([@B21]).

Metabolism, Absorption, and Bioavailability of Polyphenols
----------------------------------------------------------

After metabolism of polyphenols by Phase I and II enzymes of xenobiotic metabolism, weakly conjugated polyphenols re-enter circulation, while extensively conjugated polyphenols are excreted in the bile and enter the large intestine. The microflora hydrolyzes glycosides into aglycones and then metabolizes the aglycones into different aromatic acids, which are well absorbed across the colonic barrier ([@B35]; [@B54]; [@B21]).

The physicochemical properties of polyphenols (such as: molecular weight, extent of glycosylation and esterification) determine their intestinal absorption ([@B21]). Polyphenols in the form of esters and glycosides are absorbed less rapidly and less efficiently than aglycones and glucosides ([@B64]) due to the fact that glycosylated polyphenols are hydrophilic and thus are unable to passively diffuse through the gut wall until they are hydrolyzed ([@B73]; [@B72]). This provides an explanation for the low absorption of dietary polyphenols in the stomach as most of them are mostly present in glycosylated forms with one or more sugar residues conjugated to a hydroxyl group or the aromatic ring.

While the actual bioavailability of dietary polyphenols is yet to be fully understood, there are indications that the prostate gland is one of the tissues that readily incorporate them ([@B21]). For instance, studies carried out by [@B1] indicated that polyphenols were detected by HPLC technique in a number of tissues in mice and rats, one of which is the prostate, suggesting their bioavailability in the prostatic tissue. In another study ([@B37]) that investigated the bioavailability of tea polyphenols and theaflavins in human serum and human and mouse tissues, these polyphenols were found in the conjugated and free forms in the prostate tissue in addition to other tissues. These reports thus suggest the prostate gland to be one of the tissues where dietary polyphenols exert their biological actions.

Etiology of BPH
===============

Benign prostatic hyperplasia is a major health concern and which incidence is expected to increase in line with the greater life expectancy. A number of factors have been implicated in its etiology and which factors include: aging, hormonal alterations, metabolic syndrome, inflammation, oxidative stress ([@B83]), and more recently, suppression of apoptosis in the prostatic tissue.

Aging and BPH
-------------

Aging has been implicated as the major risk factor for the development of BPH ([@B83]; [@B3]). Several studies have demonstrated a relationship between age and markers of BPH progression ([@B74]; [@B61]).

In aging males, tissue remodeling occurs within the prostate especially in the transition zone. The most significant modifications occur in the basal cells which change their intracellular metabolism leading to prostatic enlargement. The nodular enlargement is androgen dependent and the tissue remodeling involves both the epithelium and fibromuscular stroma ([@B47]; [@B48]).

Hormonal Alteration and BPH
---------------------------

The growth and malignant transformation of the prostate gland have been reported to be influenced by sex hormone levels. Although androgens do not cause BPH, the development of BPH requires the presence of testicular androgens during prostate development, puberty, and aging ([@B48]). Reports also have it that bioavailable prostatic testosterone levels decline with age ([@B2]).

Luminal secretory cells require androgens, especially the intracellular metabolite of testosterone, DHT, for terminal differentiation and secretory functions. Testosterone is converted to DHT by the intracellular enzyme, 5α reductase type 2 ([@B83]; [@B2]; [@B3]) which is located on the prostatic nuclear membrane for both the stroma and the epithelium ([@B83]; [@B3]).

Dihydrotestosterone can act in an autocrine fashion on the stromal cells or in paracrine fashion by diffusing into nearby epithelial cells. In both of these cell types, DHT binds to nuclear androgen receptors and signals the transcription of growth factors that are mitogenic to the epithelial and stromal cells leading to prostatic hyperplasia. DHT is ten times more potent than testosterone because it dissociates from the androgen receptor more slowly. The importance of DHT in causing nodular hyperplasia is supported by clinical observations in which finasteride, an inhibitor of 5α-reductase is given to men with BPH. Therapeutic use of the 5α-reductase inhibitors markedly reduces the DHT content of the prostate and, in turn, reduces prostate volume and BPH symptoms ([@B2]).

There are indications that estrogens may also contribute to the etiology of BPH ([@B48]). Reports have it that as men age, their testicular function decreases as are their androgen levels. Furthermore, the conversion of androgen to estrogen is increased ([@B107]). In addition, while circulating levels of free estradiol remain constant in the aging man due to an age-related increase in body weight and adipose cells, the increase in the adipose cells leads to the expression of high levels of aromatase that produces estrogen conversion. The result is that the plasma estrogen to androgen ratio increases, resulting in decreased inhibition of androgens on estrogen release. The released estrogens cause increased stimulation of the prostatic stroma, resulting in excessive proliferation of the prostate and occurrence of BPH ([@B2]; [@B39]; [@B48]). Estrogen induced stimulation of prostatic growth has also been reported in dogs and monkeys ([@B45]; [@B83]; [@B3]).

BPH and Metabolic Syndrome
--------------------------

Metabolic syndrome is a well-recognized cluster of cardiovascular risk factors including obesity, hypertension, dyslipidemia, and hyperglycemia, closely associated with an increased risk of cardiovascular diseases ([@B15]).

[@B34] in their studies reported that patients with hypertension, and obesity were at risk of developing BPH. Epidemiologic studies also provided evidence that hypertensive men are more likely to develop BPH and to undergo medical and surgical therapy than healthy men ([@B68]). These studies hypothesized that the noradrenergic nerves may contribute to the functional component of the bladder outlet obstruction due to BPH.

Recent studies ([@B3]) also confirmed the frequent coexistence of metabolic syndrome and BPH. This association was suggested by the authors to be a result of the metabolic syndrome-related metabolic derangements, changes in the sex-hormone and lowered sex-hormone binding protein levels.

BPH and Oxidative Stress
------------------------

Oxidative stress refers to an imbalance between the production and detoxification of ROS/free radicals in favor of ROS/free radicals that can cause tissue damage ([@B25], [@B21]; [@B69]).

Reactive nitrogen species (RNS) and ROS are by-products of normal cellular metabolism which impact on cell signaling. Increases in the levels of these ROS and RNS induce oxidative stress ([@B100]) by causing a significant decrease in antioxidant defense mechanisms, leading to protein, lipid and DNA damage and subsequent disruption of cellular functions and cell death.

Oxidative stress has been considered to be one of the mechanisms that trigger the chain of reactions involved in the development and progression of prostatic hyperplasia. This is especially true as the human prostate tissue is vulnerable to oxidative DNA damage due to more rapid cell turnover and fewer DNA repair enzymes ([@B69]).

Recent studies carried out by [@B100], showed the levels of antioxidants in the prostatic tissue to be significantly decreased in prostatic hyperplasia ([@B100]). Furthermore, our study ([@B47]) on animal models of BPH showed significant elevation of prostatic lipid peroxidation with concomitant significant reduction of the prostatic levels of GSH, SOD, GPx, and catalase activities of BPH untreated rats and which parameters were significantly improved following treatment with finasteride or kolaviron.

BPH and Inflammation
--------------------

Inflammation is a natural defense mechanism against pathogens and it is associated with many pathogenic diseases such as microbial and viral infections, exposure to allergens, radiation and toxic chemicals, autoimmune and chronic diseases, obesity, consumption of alcohol, tobacco use, etc. ([@B97]).

Previous studies on the pathogenesis of BPH indicated the differential expression of cytokines in BPH tissue suggesting a role of inflammation in the development of BPH ([@B59]). Clinical studies carried out also support the role of inflammation in BPH. For instance, [@B18] when analyzing the clinical and pathologic data of approximately 4000 patients who had undergone transurethral resection of the prostate or open prostatectomy for BPH, found evidence of acute or chronic inflammation in 42.5% of the patients. Their studies showed a statistical significant correlation between prostate size and both acute and chronic inflammation, with neuthrophic or mononuclear infiltrates present in 29.9, 37.3, and 50% of the prostates, respectively. Other reports also correlated the degree of inflammation in patients with BPH with the prostatic size ([@B71]; [@B75]; [@B33]).

Inflammation is also one of such ways of generating free radicals/ROS in the prostatic tissue. Prostatic inflammation can cause the generation of free radicals/oxygen species such as inducible nitric oxide synthase (iNOS), reactive nitric species and ROS ([@B33]). For instance, while iNOS is not detected in normal prostate, it is expressed in the prostate of all BPH patients ([@B69]).

Prostaglandins represent a group of inflammatory mediators that result from the conversion of arachidonic acid mediated by two different isoforms of cyclooxygenase (COX) (COX-1 and COX-2), both of which forms are expressed in the prostate gland ([@B5]).

Cyclooxygenase-2 is a pro-inflammatory, inducible enzyme whose production is triggered by mitogens, cytokines, ROS, and growth factors in different cell types. Increased expression of COX-2 mRNA has been reported in BPH ([@B52]; [@B5]). Several mechanisms have been proposed to explain the role of COX-2 in prostatic hyperplasia and one of which mechanisms involves COX-2- mediated increases in prostaglandin synthesis, especially of prostaglandin E2.

In rodent models, induced prostatic inflammation was also shown to contribute to prostatic hyperplasia ([@B49]; [@B33]). These studies amongst others ([@B55]; [@B90]; [@B56]) are pointers to the contribution of inflammation to the development of BPH.

BPH and Apoptosis
-----------------

Apoptosis plays an important role in the control of cell growth and in the maintenance of tissue homeostasis ([@B70]).

There are indications that the apoptosis machinery could be a promising therapeutic target for BPH. This is because cell growth arises from either increased cell proliferation or decreased cell death ([@B2]) and BPH has been shown to result from smooth muscle and epithelial proliferation primarily within the prostatic transition zone that can produce LUTS ([@B70]).

After physiologic growth to adult size, the prostate enters a maintenance phase, where prostatic cell proliferation occurs at a daily rate of 1--2% counter balanced by an equal rate of programmed cell death ([@B91]). A lack of this balancing has been implicated in the development of BPH ([@B57]; [@B31]).

Several studies suggested that a reduction of apoptosis might occur in BPH. For instance, the study carried out by [@B58] showed that basal and luminal epithelial cells in BPH over-express Bcl-2 (apoptotic suppressor), compared to healthy prostate tissue.

Another study also showed that survivin, an inhibitor of apoptosis that counteracts cell death and controls mitotic progression was over expressed in the stromal compartment of patients with BPH ([@B91]).

Investigation into the mechanisms of action of the drugs that are currently being used in BPH management suggested possible interactions with apoptotic mechanisms ([@B31]). For example, previous studies on rat prostates showed that finasteride induced apoptosis in epithelial cells, inhibiting insulin-like growth factors (IGF) I and 1R expressions ([@B42]). These authors also showed that finasteride down-regulated the expression of the anti-apoptotic proteins- Bcl-xL and Bcl-2, making the prostate cells more susceptible to apoptosis. Other studies on BPH patients treated with finasteride further affirmed the pro-apoptotic effect of finasteride on the epithelial cells ([@B84]), and increased expression of the pro-apoptotic proteins (Caspases-3, -6, and -9) during finasteride treatment of BPH ([@B4]). Recent studies also showed increased expression of inhibitors of apoptosis proteins in human prostates with BPH ([@B82]; [@B70]).

Dietary Polyphenols and Inflammation
====================================

Inflammation is an immunological defense mechanism by which tissues respond to an insult ([@B63]). A number of polyphenols such as resveratrol, curcumin, catechins, and others have been extensively investigated as anti-inflammatory agents ([@B36]). In addition, anti-inflammatory activities of other polyphenols such as quercetin, rutin, morin, hesperetin, and hesperidin have been reported in acute and chronic inflammation in animals ([@B6]; [@B105]; [@B97]).

Polyphenols have been reported to exert their anti-inflammatory properties at multiple levels, through the modulation of mitogen-activated protein kinases (MAPK) signaling pathways and NF-κB and AP-1 transcription factors, inhibition of the production of inflammatory cytokines and chemokines, suppressing the activity of COX-2 and iNOS ([@B19]), thereby decreasing the production of ROS/RNS ([@B43]; [@B76]).

Dietary Polyphenols and Oxidative Stress
========================================

Oxidative stress occurs when there is an imbalance between the pro-oxidants and the antioxidants in a cell system in favor of the pro-oxidants which can result in damage to DNA, proteins and lipids as earlier defined.

Consumption of polyphenol rich foods, fruits, vegetables, and beverages is considered of immense benefit to human health ([@B101]) as these polyphenols are able to directly scavenge free radicals and inhibit metal-mediated free radical formation ([@B29]). When compared with endogenous antioxidants, the importance of dietary polyphenols/antioxidants *in vivo* as oxidant scavengers is considered to be minor due to their lower reduction potentials and bioavailability ([@B29]). However, these dietary polyphenols have been shown to play greater roles in the prevention of oxidative stress through mechanisms such as: (i) inhibition of redox-sensitive transcription factors \[example is nuclear factor-kB (NF-kB)\] (ii) down-regulation of pro-oxidant enzymes (example is iNOS and COX-2) and (iii) induction of Phase II enzymes ([@B29]; [@B94]; [@B21]).

In recent times, emerging evidence has indicated that apart from the antioxidant activities of polyphenols, polyphenols can also directly or indirectly strengthen the degradation of misfolded and damaged proteins.

Under normal physiological conditions, proteins undergo different conformational changes during their lifetime. Each step is assisted by chaperones and includes *de novo* folding, assembly and disassembly, transport across membranes, and targeting for degradation ([@B32]). Therefore, in optimal conditions, long-term health is maintained by protein homeostasis which is a complex network of molecular interactions that balances protein biosynthesis, folding, translocation, assembly, disassembly, and clearance ([@B17]).

The expression of many chaperones is strongly induced under conditions of oxidative stress and heat shock challenges. Therefore, they are considered to be stress proteins or heat shock proteins ([@B32]) and the ability of a cell to counteract stressful conditions is referred to as cellular stress response or heat shock response ([@B17]).

Production of heat shock proteins, including protein chaperones has been reported to be important for the folding and repair of damaged proteins, leading to cell survival conditions that would have led to apoptosis ([@B17]).

Recently, it has been shown that polyphenols can also directly or indirectly strengthen the degradation of misfolded and damaged proteins as earlier stated. This can be achieved by increasing the activity and efficiency of the cellular protein degradation machinery ([@B13]; [@B32]). Pharmacologically active polyphenols and their derivatives have been reported to play significant roles in stabilizing the protein degradation machinery at different stages which may be an attractive therapeutic strategy to halt the accumulation of misfolded proteins ([@B32]). For instance, resveratrol 20 was shown to induce the acute heat shock response by upregulating chaperones like Hsp70 ([@B79]). Curcumin 18 was reported to demonstrate cytoprotective effects and induce nuclear translocation of HSF1 ([@B98]) while also demonstrating anti-inflammatory and antioxidant activities ([@B32]).

Studies by [@B87] showed that curcumin induces hemeoxygenase-1 (HO-1, a heat shock protein) expression and activity in different brain cells via the activation of heterodimers of NF-E2-related factors 2 (Nrf2)/antioxidant responsive element pathway. Furthermore, activation of Nrf2 target genes, and particularly HO-1, in astrocytes and neurons is strongly protective against oxidative damage and cell death ([@B87]).

In another report, [@B28] showed that the polyphenol-rosamaric acid attenuated noise-induced hearing loss (which is associated with increase of ROS and lipoperoxidative damage together with the imbalance of antioxidant defenses), through activation of the redox-sensitive transcription factor nuclear factor erythroid 2-related factor 2/HO-1 pathway.

Preclinical Studies Reporting on Management of BPH with Dietary Polyphenols and their Mechanisms of Action
==========================================================================================================

Currently there are dietary polyphenols that have demonstrated 5α-reductase inhibitory properties which makes them promising agents for the management of BPH, but which activities would need to be confirmed using *in vivo* models of BPH/clinical studies. For instance, the reports of [@B38] working on cell free assays and intact cells, showed that the dietary polyphenols- myricetin, baicalein (5,6,7-trihydroxyflavone), fisetin, daidzein, kaempferol, caffeic acid phenethyl ester, octyl and dodecyl gallates inhibited human 5α-reductase activities. While *in vivo*/clinical studies will be needed to confirm these studies, these authors speculated that since these polyphenols were effective on whole cells, they could be capable of modulating the activity of 5α-reductase *in vivo*. Studies conducted by [@B77] also confirmed the 5α-reductase inhibitory activity of kaempferol and caffeic acid phenethyl ester as previously reported by [@B38].

On the other hand, there are dietary polyphenols that were reported in preclinical studies to possess the potentials of suppressing BPH. Typical examples are the isoflavonoids- genistein, biochanin A and equol and the lignan- enterolactone which were reported to ameliorate BPH in BPH tissue homogenates through inhibition of 5α-reductase activity ([@B26]).

ACTICOA powder (contains mostly flavonols), a cocoa polyphenol extract was demonstrated by [@B9] to be useful in ameliorating testosterone propionate-induced prostate hyperplasia in rats.

Again, soybean isoflavones were reported to inhibit BPH and increase the expressions of nitric oxide and nitric oxide synthase ([@B103]).

Similarly, quercetin (from onions, red wine, tea, cranberry, and citrus fruits) was reported to suppress BPH in preclinical studies ([@B96]; [@B10]) although the mechanism of action is yet to be ascertained.

In another report, flavocoxid, a flavonoid from *Scutellaria baicalensis* (Chinese skullcap) and *Acacia catechu* (black catechu), respectively, was reported to demonstrate anti-BPH properties and the mechanism of action was reported to involve decreasing growth factor expression and inhibition of COX-2 and 5-lipoxygenase activities in the prostatic tissue of BPH rats ([@B5]).

Equol (4′,7-isoflavandiol), a polyphenol/isoflavonoid molecule derived from soya and intestinal metabolism ([@B7]), was reported to suppress BPH in experimental studies. According to the authors, this polyphenol has potent antioxidant and anti-aging properties to decrease prostatic irritation and potentially neoplastic growth. The mechanism of its ameliorating action on BPH was reported as its specific binding to 5α-DHT by sequestering 5α-DHT from the androgen receptor, thus decreasing androgen hormone actions to improve prostate health by acting as a selective androgen modulator ([@B20]).

Lycopene, a polyphenol commonly found in tomato, was shown to decrease BPH in animal models of BPH. The mechanism of action was reported to be stimulation of increased expression of the pro-apoptotic protein- caspase-3 and suppression of inflammatory marker- IL-6 ([@B70]).

In another study ([@B41]), anthocyanins from black soybean were reported to suppress prostatic hyperplasia in rats induced with BPH. The mechanism of action was reported by the authors to involve suppression of cellular proliferation through induction of apoptosis in the prostatic tissue.

In a more recent study using animal models, we showed the beneficial role of kolaviron, a polyphenol and a biflavonoid complex from *Garcinia kola* in the management of BPH in BPH challenged rats ([@B47]; [@B48]). The mechanism of action was found to involve inhibition of 5-alpha reductase and oxidative stress in the prostatic tissue. Furthermore, [@B46] in their recent study reported that epigallocatechin-3-gallate had protective effects against testosterone induced BPH in rats and against BPH in metabolic syndrome rats. The mechanism of the BPH protective action of this polyphenol on the experimental BPH induced rats was reported by the authors to involve repair of the antioxidant defense mechanisms (superoxide dismutase and glutathione peroxidase) in the prostate with concomitant diminution of prostatic levels of malonaldehyde; diminution of the prostatic levels of the inflammatory markers- interleukin (IL)*-*Iβ, IL-I6, tumor necrosis factor-α (TNF*-*α); inhibition of IGF-I and IGF-II as well as upregulation of peroxisome proliferator-activated receptors (PRAR) -- α and PPAR-γ that have been shown to contribute to apoptosis. Another very recent study ([@B81]) also reported the treatment effects of flaxseed-derived secoisolariciresinol diglycoside (a lignan extracted from flaxseed) and its metabolite enterolactone on BPH. The mechanistic basis for its anti-BPH activity was reported by the authors to involve stimulation of increased expression of G-protein-coupled estrogen receptor 1 (GPER) that has been reported to decrease cell proliferation by activating apoptosis in some cells ([@B14]).

Clinical Studies/Management of BPH with Dietary Polyphenols
===========================================================

Until now, the concept of management of BPH using dietary polyphenols has been under debate due to a number of clinical studies that gave contrary results as well as the adverse effects some of these polyphenols could pose following long term exposure.

For instance, in the review by [@B16], they listed some phytotherapies that are used in BPH management such as quercetin and others but showed the lack of clinical effects of some of these phytotherapies although clinical study conducted on BPH management with quercetin ([@B93]) and reviewed by [@B16], did not deny the anti-BPH effect of quercetin. Moreover, the double-blind randomized clinical trial conducted by [@B30] provided evidence of the efficacy of quercetin in the treatment of BPH.

Again, clinical studies conducted on BPH management with resveratrol as reported by [@B53] did not support the management of BPH with this polyphenol.

However, some other clinical studies carried out on BPH management with some dietary polyphenols provided evidence of their usefulness in the management of BPH.

For example, in a study carried out on the effects of a low oral dose of equol supplement (6 mg, twice a day with meals) for 4 weeks in a total of 18 men (49--60 years old) with moderate or severe BPH ([@B60]), it was shown that a low dose of equol positively improved moderate to severe BPH symptoms according to the IPSS indices. In moderately symptomatic men, 5 out of 7 of the IPSS parameters significantly improved by 4 weeks of equol treatment while in severely symptomatic men, all 7 of the IPSS parameters significantly improved with 4 weeks of equol treatment. In addition, their study also showed that 5α-DHT levels declined by 21% in severely symptomatic men.

In a randomized, double-blind, placebo-controlled trial that investigated the effects of lycopene supplementation in elderly men diagnosed with BPH ([@B89]), it was reported that lycopene inhibited BPH progression and ameliorated the BPH symptoms in the patients at a dose of 15 mg/day for 6 months and which finding was supported by later experimental studies conducted by [@B70] on the management of BPH with lycopene. Furthermore, the authors ([@B89]) also reported the lycopene supplements to be safe and well tolerated.

Similarly, in a 4 months randomized, double-blind, placebo-controlled clinical trial carried out in 87 subjects with BPH receiving treatment dosages of 0 (placebo), 300, or 600 mg/day of the flaxseed lignan extract (secoisolariciresinol diglucoside (SDG) ([@B106]), the authors showed that for the 0, 300, and 600 mg/day SDG groups, respectively, the International Prostate Symptom Score decreased by -3.67 ± 1.56, -7.33 ± 1.18, and -6.88 ± 1.43 (mean ± SE, *P* = 0.100, \<0.001, and \<0.001 compared to baseline), while the Quality of Life score improved by -0.71 ± 0.23, -1.48 ± 0.24, and -1.75 ± 0.25 (mean ± SE, *P* = 0.163 and 0.012 compared to placebo. In addition, the authors suggested the therapeutic efficacy of this polyphenol to be comparable to that of the commonly used intervention agents of alpha1A-adrenoceptor blockers and 5α-reductase inhibitors. The finding by these authors with respect to BPH management using this polyphenol was further affirmed by the later experimental study conducted by [@B81].

Similarly, the double-blind randomized clinical trial conducted by [@B30] provided evidence of the efficacy of quercetin in the treatment of BPH as earlier stated.

Other clinical studies carried out supported the use of phytotherapies from different plants such as Eviprostat ([@B67]), *Pygeum africanum* extract ([@B12]), Stinging nettle root extract (Bazotonuno) ([@B88]), PR-2000 (*Tribulus terrestris*) ([@B85]), and others in the management of BPH but which are beyond the scope of this review as the actual polyphenols in these phytotherapies were not indicated in these studies.

Adverse Effects Associated with Uncontrolled and Long-Lasting Supplementation with Dietary Polyphenols
======================================================================================================

While the contribution of some dietary polyphenols in the management of BPH has been indicated in this review as supported by clinical findings, it must also be emphasized that non-regulated and long-lasting supplementation with some dietary polyphenols could lead to potential harmful effects due to possible interactions with cytochrome P450 (CYP) enzymes ([@B65]).

Amongst the CYP enzymes which are responsible for the metabolism of a wide array of endogenous substances, (example-steroids, hormones, lipids, and bile acids), xenobiotics (example-drugs and pollutants from the environment), and dietary products and/dietary polyphenols, CYP 3A4 has been shown to be the major enzyme that is involved in the metabolism of drugs and xenobiotics in the liver and gut ([@B62]). It has also been shown to be expressed in the prostate, breast, gut, colon, small intestine, and the brain ([@B27]; [@B62]).

In recent times, studies have also suggested possible interactions between dietary polyphenols and CYP 3A4, which could lead to some adverse effects.

For instance, [@B66] reported that curcumin and its derivatives inhibit the activity of CYP3A4 and other drug-metabolizing enzymes such as: glutathione-*S*-transferase and UDP-glucuronosyltransferase. These authors reported that inhibition by curcumin, alone or in combination with piperine, of CYP3A4 could be harmful, especially during prolonged usage.

[@B51] in their study, showed the inhibitory effects of polyphenols on human CYP3A4 and CYP2C9 activity *in vitro* which inhibitory actions were reported by the authors to involve the formation of a covalent bond between the polyphenol and the CYP3A4 molecule, leading to the inactivation of the enzyme, or reversible binding that causes reversible inhibition. Similarly, the-flavonols kaempferol, quercetin, and galangin were reported to inhibit CYP3A4-mediated metabolism of xenobiotics *in vitro* ([@B92]; [@B62]). Furthermore, inhibitory effects of catechins on CYP3A4 were reported in some studies ([@B51]; [@B104]), although no specific mechanisms of action were reported in these studies.

One thing most of these studies reporting on the interaction of polyphenols with CYP enzymes have shown is the need for controlled/regulated use of polyphenols for therapeutic purposes.

**Table [1](#T1){ref-type="table"}** shows the dietary polyphenols identified in this review with 5α-reductase inhibitory activities but which activities would need to be confirmed using *in vivo*/clinical studies; **Table [2](#T2){ref-type="table"}** summarizes the mechanisms through which the dietary polyphenols identified in the preclinical studies with BPH suppressing properties exert their biological effects; the structures of the polyphenols with 5α-reductase inhibitory properties are shown in **Figure [1A](#F1){ref-type="fig"}** while the structures of the polyphenols identified in the preclinical studies with BPH suppressing properties are shown in **Figure [1B](#F1){ref-type="fig"}**.

###### 

Dietary polyphenols identified with 5α-reductase inhibitory actions.

  Polyphenols                    Source                                                    Activity
  ------------------------------ --------------------------------------------------------- ------------------------------------------
  Myricetin                      Red wine                                                  5α-reductase inhibition ([@B38])
  Baicalein                      *Scutellaria baicalensis* and *Scutellaria lateriflora*   5α-reductase inhibition ([@B38])
  Fisetin                        Strawberries, apples, grapes                              5α-reductase inhibition ([@B38])
  Daidzein                       Soybeans                                                  5α-reductase inhibition ([@B38])
  Kaempferol                     Apples, broccoli, onions, tomatoes                        5α-reductase inhibition ([@B38]; [@B77])
  Caffeic acid-phenethyl ester   Propolis                                                  5α-reductase inhibition ([@B38]; [@B77])
  Octyl gallate                  Octanol and gallic acid (produced from plant tannins)     5α-reductase inhibition ([@B38])
  Dodecyl gallates               Gallic acid (from plan tannins)                           5α-reductase inhibition ([@B38])

###### 

Dietary polyphenols identified with BPH suppressing properties.

  Polyphenol                         Source                                           Mechanisms of action
  ---------------------------------- ------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Epigallocatechin-gallate           Green tea                                        Suppression of oxidative stress, diminution of inflammatory markers (IL-Iβ, IL-I6, and TNF-α; inhibition of IGF-I and IGF-II and upregulation of PPAR-α and PPAR-γ ([@B46])
  Lignan                             Flaxseeds, sesame seeds                          5α-reductase inhibition ([@B26])
  Genistein                          Fava beans, soybeans                             5α-reductase inhibition ([@B26])
  Biochanin A                        Soy, Peanuts                                     5α-reductase inhibition ([@B26])
  Enterolactone                      Flaxseed and sesame sees                         5α-reductase inhibition ([@B26])
  Flavocoxid                         *Scutellaria baicalensis* and *Acacia catechu*   Inhibition of growth factor expression and suppression of inflammation through inhibition of cyclooxygenase-2 and 5-lipoxygenase activities ([@B5])
  Equol                              Soya                                             Binding to 5α-DHT by sequestering 5α-DHT from the androgen receptor ([@B26]; [@B20])
  Anthocyanin                        Soya                                             Suppression of cellular proliferation through induction of apoptosis ([@B41]).
  Lycopene                           Tomato                                           Upregulation of caspase-3 and suppression of IL-6 ([@B70])
  Kolaviron                          *Garcinia kola*                                  Inhibition of 5α-reductase and suppression of oxidative stress in the prostatic tissue ([@B47])
  Secoisolariciresinol diglucoside   Flaxseed                                         Stimulation of increased expression of G-protein-coupled estrogen receptor 1 ([@B81])

![**(A)** Structures of the polyphenols with 5α-reductase inhibitory actions. **(B)** Structures of polyphenols with BPH suppressing actions in preclinical studies.](fphar-08-00234-g001){#F1}

Conclusion
==========

While this review does not state emphatically that dietary polyphenols could replace the need for the existing therapies in the management of BPH, it suggests the promise some dietary polyphenols hold in BPH management which could be explored by researchers working in this field.
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